Stephen D Gillies Selected Research

lorukafusp alfa

1/2019	Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.
10/2018	Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
8/2013	Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
12/2012	Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
12/2011	Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
11/2011	Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.
4/2011	Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.
12/2010	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
11/2010	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
9/2009	Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen D Gillies Research Topics

Disease

39	Neoplasms (Cancer) 01/2022 - 01/2002
23	Neuroblastoma 01/2022 - 06/2002
11	Melanoma (Melanoma, Malignant) 01/2022 - 11/2004
4	Hypotension (Low Blood Pressure) 12/2012 - 11/2004
4	Neoplasm Metastasis (Metastasis) 06/2011 - 01/2003
3	Lymphocytosis 12/2012 - 11/2004
2	Necrosis 01/2017 - 05/2011
2	Rhabdomyosarcoma 01/2017 - 07/2015
2	Ovarian Neoplasms (Ovarian Cancer) 12/2011 - 05/2004
2	Hypoxia (Hypoxemia) 11/2010 - 11/2004
2	Pain (Aches) 11/2010 - 04/2010
2	Hyperbilirubinemia 11/2010 - 11/2004
2	Hypersensitivity (Allergy) 11/2010 - 08/2005
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Amyloid Plaque 01/2020
1	Sarcoma (Soft Tissue Sarcoma) 07/2015
1	Experimental Melanoma 04/2013
1	Renal Insufficiency (Renal Failure) 12/2012
1	Oliguria 12/2012
1	Residual Neoplasm 12/2012
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2011
1	Exanthema (Rash) 11/2010
1	Hyperalgesia 04/2010
1	Colonic Neoplasms (Colon Cancer) 08/2009
1	Fever (Fevers) 07/2009
1	Obesity 01/2005
1	Body Weight (Weight, Body) 01/2005
1	Thrombocytopenia (Thrombopenia) 11/2004
1	Arthralgia (Joint Pain) 11/2004
1	Hypophosphatemia 11/2004

Drug/Important Bio-Agent (IBA)

21	Interleukin-2 (IL2)IBA 01/2022 - 05/2003
15	lorukafusp alfaIBA 01/2019 - 01/2004
12	Monoclonal AntibodiesIBA 01/2022 - 03/2006
11	CytokinesIBA 01/2018 - 10/2002
10	Proteins (Proteins, Gene)FDA Link 01/2017 - 10/2002
5	AntibodiesIBA 01/2020 - 05/2005
4	Immunoglobulin G (IgG)IBA 01/2020 - 09/2004
4	dinutuximabIBA 01/2018 - 10/2007
4	tucotuzumab celmoleukinIBA 12/2011 - 05/2004
4	Interleukin-2 Receptors (IL 2 Receptor)IBA 12/2011 - 11/2004
3	Interleukin-12 (IL 12)IBA 01/2017 - 04/2007
3	Biological ProductsIBA 07/2009 - 05/2004
2	LigandsIBA 01/2018 - 12/2010
2	Therapeutic UsesIBA 01/2018 - 05/2004
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2018 - 06/2002
2	AntigensIBA 04/2013 - 05/2005
2	Epithelial Cell Adhesion MoleculeIBA 12/2011 - 05/2004
2	ResveratrolIBA 11/2011 - 05/2011
2	Transaminases (Aminotransferases)IBA 11/2010 - 11/2004
2	Dopamine (Intropin)FDA LinkGeneric 11/2010 - 03/2006
1	carboxyaminoimidazole ribotide (CAIR)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Neoplasm AntibodiesIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	Isotretinoin (Accutane)FDA LinkGeneric 01/2018
1	EpitopesIBA 01/2017
1	OligodeoxyribonucleotidesIBA 01/2017
1	Cytotoxins (Cytolysins)IBA 01/2017
1	Interleukin-7 (Interleukin 7)IBA 07/2015
1	Histones (Histone)IBA 07/2015
1	Recombinant ProteinsIBA 08/2013
1	C-Reactive ProteinIBA 12/2012
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 12/2011
1	Actins (F Actin)IBA 12/2011
1	DNA (Deoxyribonucleic Acid)IBA 11/2011
1	EMD 521873IBA 06/2011
1	KIR ReceptorsIBA 12/2010
1	Complement System Proteins (Complement)IBA 04/2010
1	GangliosidesIBA 04/2010
1	Complement C6 (Complement 6)IBA 04/2010
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 04/2010
1	Anaphylatoxin C5a ReceptorIBA 04/2010
1	Opiate AlkaloidsIBA 04/2010
1	Neoplasm Antigens (Tumor Antigens)IBA 12/2008
1	EndostatinsIBA 03/2008
1	Immunoconjugates (Immunoconjugate)IBA 10/2007
1	eicosaneIBA 10/2007
1	DiaminesIBA 10/2007
1	Chelating AgentsIBA 10/2007
1	RadiopharmaceuticalsIBA 10/2007
1	sialogangliosidesIBA 10/2007
1	Fibronectins (Fibronectin)IBA 04/2007
1	DisulfidesIBA 04/2007
1	oncofetal fibronectinIBA 04/2007
1	Protein Isoforms (Isoforms)IBA 04/2007
1	HMW-MAAIBA 08/2005
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 08/2005
1	Fc Receptors (Fc Receptor)IBA 05/2005
1	LeptinIBA 01/2005

Therapy/Procedure

19	Immunotherapy 01/2022 - 01/2003
14	Therapeutics 01/2022 - 01/2004
2	Induction Chemotherapy 01/2022 - 11/2019
2	Radiotherapy 01/2022 - 01/2016
1	Neoadjuvant Therapy 01/2022
1	Drug Tapering 12/2012
1	Intravenous Infusions 12/2012
1	Radiofrequency Ablation 08/2009
1	Aftercare (After-Treatment) 08/2009
1	Biological Therapy 03/2007